Phillipe Aftimos

12PUBLICATIONS
163CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHealth and ecological risk assessmentPanel data analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Jul 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

|Jul 06, 2026
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

|Dec 22, 2025
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01).

Chiara Biagioni, Danai Fimereli, Alexandre Irrthum

|Sep 24, 2025
Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need.

Alexander D J Thooft, Sofie Joris, Celine Jacobs

|Oct 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).

Nicholas Turner, Cristina Saura, Philippe Aftimos

Pageof 2

Frequent Collaborators

3 joint publications

Virginia Kaklamani

3 joint publications

Patrick Neven

3 joint publications

Erika P Hamilton

3 joint publications

Joyce O'Shaughnessy